Montelukast Teva (Montelukast Sodium)

• Montelukast Teva is a leukotriene receptor antagonist used in the management of several respiratory and allergic conditions.
• Asthma: provides maintenance therapy that reduces the frequency and severity of asthma symptoms.
• Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity.
• Allergic rhinitis: relieves nasal congestion, sneezing, itching and rhinorrhea associated with seasonal or perennial allergies.

• Montelukast selectively antagonizes the cysteinyl leukotriene receptor CysLT1, blocking the action of leukotrienes that cause bronchoconstriction, mucus secretion, vascular permeability and inflammatory cell recruitment in the airways. By inhibiting this pathway, it reduces airway narrowing and inflammation, improving respiratory function in susceptible patients.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache
• Abdominal pain
• Nausea
• Dizziness
• Fatigue
• Cough

Serious or Rare Side Effects

• Angioedema or severe allergic reactions
• Eosinophilic granulomatosis with polyangiitis (Churg‑Strauss syndrome)
• Severe rash or Stevens‑Johnson syndrome
• Hepatic injury
• Mood changes, including suicidal thoughts

• Montelukast should be used with awareness of specific safety considerations.
• Pregnancy: safety category is unknown; use only if the potential benefit justifies the risk.
• Breastfeeding: unknown excretion in milk; weigh benefits against possible risks.
• Liver impairment: dose adjustment may be required; monitor hepatic function.
• Age restrictions: not recommended for children under 12 years for asthma maintenance therapy.
• Drug interactions: review concomitant medications for potential interactions.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines; some combinations require avoidance while others need monitoring.

Major Interactions (Avoid)

• Rifampin or other strong CYP3A4 inducers: may markedly reduce montelukast plasma concentrations.
• Ketoconazole or other potent CYP3A4 inhibitors: may increase montelukast exposure and risk of adverse effects.

Moderate Interactions (Monitor Closely)

• Concurrent use with other leukotriene pathway inhibitors (e.g., zafirlukast): may increase risk of liver enzyme abnormalities.
• Phenobarbital: may modestly lower montelukast levels.
• Antidepressants (e.g., fluoxetine): monitor for neuropsychiatric symptoms.